Novo Nordisk A/S/ DK0062498333 /
14/06/2024 9:35:42 | Diferencia +7.95 | Volumen | Bid10:09:04 | Ask10:09:03 | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
992.00DKK | +0.81% | 140 Volumen de negocios: 138,692.95 |
976.70Volumen de oferta: 197 | 986.80Tamaño/ Volumen/ Formato de Ask: 195 | 3386.91 mil millonesDKK | 0.95% | 52.81 |
GlobeNewswire
9:11
Early Signals by WOO X: BTC Faces Downward Trend While TON Ecosystem Reaches New Highs with Surging ...
GlobeNewswire
9:01
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients ...
GlobeNewswire
9:00
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investi...
GlobeNewswire
9:00
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patie...
GlobeNewswire
9:00
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimila...
GlobeNewswire
8:00
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ T...
GlobeNewswire
7:00
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EH...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página